Veterinarians
Give your patients more good years.
No surgery. No drugs. No limits.
Pelara LIFU is the first portable LIFU platform built for veterinary practice, delivering 1mm-precision therapy to any tissue depth, for six indications, with no sedation required.
1mm
Focal precision deeper & more accurate than any laser
6
Treatable indications on one platform
0
Portable LIFU competitors in US animal medicine
~10 min
Average session time, tech administered
THE INDICATIONS NO OTHER DEVICE CAN REACH
| INDICATION | STATUS | DESCRIPTION |
|---|---|---|
| Chronic pain | Launch indication Q4 2026 | OA, neuropathic pain, DJD. LIFU modulates pain circuits at 1mm precision, reducing central sensitization without NSAIDs. |
| MSK healing | Launch indication Q4 2026 | Tendon, ligament, and bone repair. Mechanotransduction stimulates cellular repair, including post-TPLO and equine deep tendon injuries. |
| Neuro-modulation | Research evidence in development | Tendon, ligament, and bone repair. Mechanotransduction stimulates cellular repair, including post-TPLO and equine deep tendon injuries. |
| Oncology | Research evidence in development | Non-invasive tumor ablation and immune activation. Viable for patients who cannot tolerate surgery or chemotherapy. |
| Cardiac | Research evidence in development | Stellate ganglion modulation for arrhythmia management. Published canine safety data from Yu et al. (2017). |
| Wound healing | Research evidence in development | Accelerated tissue repair and anti-inflammatory effects via acoustic mechanotransduction at the wound site. |
HOW IT WORKS
01
Plan
PelaraOS AI maps the target anatomy and guides the treatment protocol in minutes.
02
Position
Flexible transducer placed on the patient, no sedation required.
03
Treat
~10 minute session, tech-administered. LIFU delivers focused acoustic energy to the exact target.
04
Track
PelaraOS logs outcomes, and benchmarks results against your outcomes registry.
Our Purpose
DESERVING PATIENTS
THE SCIENCE BEHIND IT
| MSK · Large animal model Hellman et al. (2021) — Journal of Neurosurgery First large-animal LIFU neuropathic pain study. DRG targeting in swine (14–20 kg) eliminated pain-guarding behaviors for 1 month, reduced allodynia for 5 days, with <2°C tissue heating and zero histological damage. Swine DRG depth matches medium-large dog anatomy directly. |
| Oncology · Canine clinical trial Carroll et al. (2022) — International Journal of Hyperthermia 20 client-owned dogs with soft tissue sarcomas and mast cell tumors treated with focused ultrasound. Successful ablation, immune gene expression changes, and well-tolerated protocol. Establishes clinical feasibility of focused US in canine patients. |
| Cardiac · Canine model Yu et al. (2017) — Heart Rhythm, 14(6) LIFU applied to the left stellate ganglion in post-MI dogs reduced arrhythmias and modulated neural activity — with no histological damage. Direct canine evidence of LIFU safety and neural modulation efficacy. |
Frequently Asked Questions
Does the animal need to be sedated?
No. The transducer design allows comfortable placement and treatment without sedation for the majority of canine and equine patients. Protocol guidance covering species-specific positioning is provided during onboarding.
How long does a session take?
Most treatment sessions run ~10 minutes depending on the indication and body area. Sessions are technician-administered once your team completes Pelara’s certification program, freeing the DVM’s time for other cases.
What species can be treated?
The Pelara LIFU platform launches with companion animal (canine and feline) and equine protocols. Additional species protocols are in development. The modular design adapts across body sizes and species with different strap configurations.
What training is required?
All practices complete Pelara’s DVM Certification, a 4-hour hybrid (online + hands-on) course covering LIFU science, device operation, protocol selection, and safety. Technician certification is a separate 2-hour online track. CE credit through RACE approval is in process.
What makes Pelara different from shockwave?
Pelara LIFU delivers 1mm focal precision to any tissue depth with zero mechanical trauma compared to shockwave’s zone-level targeting and deliberate tissue disruption mechanism. LIFU also covers six indications vs. shockwave’s primary focus on MSK and pain, and includes the PelaraOS AI outcomes platform that shockwave systems do not offer.
Have additional inquiries?
We are here to help. Let’s engage in a conversation.